T he development of cardiac allograft arteriosclerosis is the main reason for the poor long-term survival of heart transplant patients. The pathogenesis of allograft arteriosclerosis is not completely understood, but immunologic and nonimmunological injuries are believed to trigger a fibroproliferative response in a transplanted heart. This includes upregulation of cytokines and growth factors and the recruitment and proliferation of vascular smooth muscle cells (VSMCs) in the intima of injured arteries. In addition, fibroblasts proliferate and deposit extracellular matrix (ECM) leading to cardiac fibrosis. 1 Platelet-derived growth factors (PDGF) are strong mitogens for VSMCs 2,3 and fibroblasts, 4 -6 and are essential in normal embryonic development, wound healing, and angiogenesis in cooperation with other growth factors. [7] [8] [9] [10] [11] The PDGF signaling system consists of PDGF-A and PDGF-B ligands, and of the more recently-characterized PDGF-C and PDGF-D ligands as well as their receptors PDGFR-␣ and PDGFR-␤. [12] [13] [14] PDGF-A and PDGF-C signal through PDGFR-␣. 11 In contrast, the ECM-binding PDGF-B, and the soluble PDGF-D, to a lesser extent, are responsible for PDGFR-␤mediated effects. 13, 15, 16 Furthermore, PDGF ligands have a regulatory role in several pathological conditions such as atherosclerosis, rheumatoid, and fibroproliferative diseases, 17, 18 and tumor growth. 19, 20 There is evidence suggesting that PDGF mediates pathological fibroproliferation in transplanted hearts. PDGF-A is increased in human cardiac allografts-predominantly in myocytes and vascular wall. 21 Also, peripheral blood mononuclear cells derived from heart transplant patients with allograft arteriosclerosis induce donor-derived endothelial cells to produce PDGF-A. 22 Experimental heart transplantation studies show that acute and chronic rejection induce moderate PDGF-A but only mild PDGF-B expression in mononuclear inflammatory cells, media, and intimal cells of arteries. 23 PDGFR-␣ and -␤ are induced mostly in the allograft vasculature, but also in interstitial and perivascular inflammatory cells. 23 In addition, intragraft expression of PDGF-A, PDGFR-␣, and -␤ correlates with cardiac allograft arteriosclerosis, 23 and unselective PDGF receptor tyrosine kinase inhibitors reduce cardiac allograft arteriosclerosis. 24 Interestingly, treatment with monoclonal antibodies against PDGFR-␣-but not against the ligand PDGF-A solely-decreases formation of allograft arte-riosclerosis, 25 suggesting a synergic role of PDGF-C through PDGFR-␣. Currently, the specific effects of different PDGF ligands in heart transplants remain unknown, and there are no reports on the role of the newly found PDGF-C and PDGF-D ligands in solid organ transplants.
We examined the expression of all PDGF family members in acutely-and chronically-rejecting rat cardiac allografts. We also investigated the functional roles of PDGF-A-D ligands in chronic rejection. 26 We found that ligands PDGF-A, PDGF-C, and PDGF-D were induced in the graft vasculature during chronic rejection in cardiac allografts. In addition, adeno-associated virus-2 (AAV2)-mediated gene transfer of ligands PDGF-A, PDGF-C, and PDGF-D upregulated TGF-␤1 mRNA expression and enhanced fibrosis and arteriosclerosis in cardiac allografts. Our results suggest that inhibiting the signaling of all PDGF-ligands but of PDGF-B may be needed to prevent manifestations of chronic rejection in cardiac allografts.
Methods

Experimental Design
For expanded Materials and Methods, please see http://atvb. ahajournals.org. The rat heterotopic heart transplantation model was used. 23 Expression of PDGF ligands and receptors was investigated in nontransplanted hearts, acutely-rejecting cardiac allografts, chronically-rejecting allografts, and their syngeneic controls with quantitative RT-PCR (LightCycler, Roche) and immunohistochemistry (Vectastain Elite ABC Kit, Vector Laboratories).
The effect of PDGF ligand overexpression was investigated by AAV2-mediated gene transfer during harvesting (EGFP, PDGF-A-D). 26 Recipients were treated with suboptimal subcutaneous CsA and allografts were harvested at 100 days for morphometric determination of arteriosclerosis and myocardial cross-sectional area (Zeiss Axiovision 4.4, Carl Zeiss GmbH), fibrosis grade (0 -3), immunohistochemical quantification of graft-infiltrating inflammatory cells, and mRNA levels of angiogenic, fibrotic, and inflammatory cytokines (quantitative RT-PCR). Allograft function grade (0 -4) was determined by daily palpation.
Results
PDGFR-␣ mRNA Is Upregulated in Acutely-Rejecting, and PDGF-A and PDGF-C mRNA in Chronically-Rejecting Cardiac Allografts
Real-time RT-PCR showed that in acute rejection, allograft PDGFR-␣ mRNA levels were significantly upregulated (PϽ0.05; Figure 1A ) and PDGF-D mRNA levels were downregulated (PϽ0.05; Figure 1F ), when compared to their syngenic controls, whereas no significant changes were seen in the mRNA levels of PDGFR-␤ or PDGF-A, PDGF-B, and PDGF-C ( Figure 1B through 1E ). In chronically-rejecting allografts, PDGF-A (PϽ0.05; Figure 1C ) and PDGF-C (PϽ0.05; Figure 1E ) mRNA levels were doubled, when compared to their syngenic controls, whereas no changes were seen in the mRNA levels of PDGFR-␣, PDGFR-␤, and PDGF-B ( Figure 1A , 1B, and 1D), and the mRNA levels of PDGF-D were significantly reduced (PϽ0.05; Figure 1F ).
Acute Rejection Induces Prominent PDGFR-␣ Immunoreactivity in the Media of Coronary Arteries
Immunohistochemical stainings were next performed to localize and quantify PDGF ligand and receptor protein expres-sion in rat allografts. A combined immunohistochemical score that reflects the total expression in the whole transplant is given in Figure 2 , and a detailed analysis of the immunoreactivity grade in different cell types in the supplemental Figure I Acute rejection significantly increased the combined immunohistochemical score of PDGFR-␣ expression ( Figure  2A ), and PDGFR-␣ immunoreactivity mainly localized to the media of coronary arteries (supplemental Figure IA) . Acute rejection did not affect the combined immunoreactivity score of PDGFR-␤ ( Figure 2B ), but a detailed analysis showed that PDGFR-␤ immunoreactivity was significantly in- creased in graft-infiltrating mononuclear inflammatory cells (supplemental Figure IF) and decreased in the media of arteries (supplemental Table I ).
Acute rejection significantly increased the combined PDGF-A immunoreactivity score ( Figure 2C ), and PDGF-A immunoreactivity mainly localized to allograft-infiltrating mononuclear inflammatory cells (supplemental Table I ). During acute rejection, capillary endothelium almost totally lost its strong PDGF-D immunoreactivity seen in nontransplanted control hearts and syngrafts, which may explain the significant downregulation observed in the PDGF-D mRNA expression ( Figure 1F ).
Chronic Rejection Induces Intense Expression of All PDGF Ligands and Receptors, But Not of PDGF-B, in the Intima of Coronary Arteries
Immunohistochemical analysis revealed that chronic rejection significantly increased the combined immunohistochemical score of PDGFR-␣, PDGF-A, and PDGF-C (Figure 2A Here, as well as in acute rejection, the markedly reduced PDGF-D expression in the capillary endothelium could explain the reduced PDGF-D mRNA production seen in chronically-rejecting cardiac allografts ( Figure 1F ). Moreover, PDGF-B immunoreactivity remained low in graft infiltrating mononuclear inflammatory cells and was markedly reduced in the media of coronary arteries (supplemental Figure IM ).
AAV2-Mediated PDGF Ligand Gene Transfer in Rat Cardiac Allografts
To gain insight in the functional effects of different PDGF ligands, we perfused coronary arteries of cardiac allografts with adeno-associated virus-2 (AAV2) vectors encoding either the control gene EGFP, or PDGF-A, -B, -C, or -D. The cDNAs of various PDGF ligands were cloned into an AAV-2 vector under the control of a CMV promoter (supplemental Figure IIA) , and the AAV2-mediated production of different PDGF ligands at protein level in vitro was confirmed from the media of the AAV2-transduced 293T cells using respective PDGFR-␣ and PDGFR-␤ immunoglobulins (supplemental Figure IIB ). As AAV2-mediated transgene expression increases gradually over the first month and remains stable thereafter, 26 we extended the end point of our chronic rejection model from 60 to 100 days to ensure prolonged PDGF expression in the cardiac allografts. At 100 days, RT-PCR with vector-specific forward primers confirmed the AAV-mediated transcription of PDGF-A-D in the cardiac allografts of the corresponding groups ( Figure 3A ). In addition, 9.28% (range 5.84% to 15.41%) of cardiomyocytes in the AAV2-EGFPperfused allografts showed immunoreactivity for GFP ( Figure  3B through 3E) .
To determine whether AAV-PDGF perfusion changed allograft function, we analyzed the cardiac allograft functional score that was obtained by daily abdominal palpation of the transplanted hearts. Perfusion of AAV2-PDGF-A significantly decreased the allograft contractile function score (PϽ0.05; Figure 3F ). In addition, AAV2-PDGF-A perfusion decreased the 100-day allograft survival to 50% (survival 4 out of 8, PϽ0.05; Figure 3G ) and AAV2-PDGF-D perfusion to 85.7%, whereas all allografts perfused with AAV2-EGFP, -PDGF-B, and -PDGF-C survived the whole experimental period.
AAV2-Mediated PDGF-A, PDGF-C, and PDGF-D Gene Transfer Enhances Cardiac Allograft Arteriosclerosis and Fibrosis
As PDGF-ligands are potent mitogens for smooth muscle cells and fibroblasts, we next investigated the effect of AAV2-mediated PDGF-A-D gene transfer on myocardial Figure  4A ), AAV2-PDGF-C (PϽ0.05), and AAV2-PDGF-D (PϽ0.05) resulted in more than a 2-fold increase in myocardial cross-sectional area, when compared to the AAV2-EGFP controls. Moreover, the grade of cardiac fibrosis was more than 2-fold in hearts perfused with AAV2-PDGF-C (PϽ0.05; Figure 4B ) and AAV2-PDGF-D (PϽ0.05) when compared to the control hearts. Mild arteriosclerotic changes were seen at day 100 in allografts perfused with AAV2-EGFP or AAV2-PDGF-B ( Figure 4C ). On the contrary, perfusion with AAV2-PDGF-A (PϽ0.01), AAV2-PDGF-C (PϽ0.05), or AAV2-PDGF-D (PϽ0.001) markedly increased the intensity of arteriosclerotic changes ( Figure 4C ). Collectively, these results indicate that PDGF-A, PDGF-C, and PDGF-D-but not PDGF-B-induce pathological fibroproliferative effects in transplanted hearts.
AAV2-Mediated PDGF-A and PDGF-D Gene Transfer Increases Cardiac Allograft Inflammation
As PDGF ligands may regulate the entry of inflammatory cells into the allograft by recruitment of PDGFR ϩ inflammatory cells or effects on vascular stability, we next determined the intensity of graft inflammation by CD4, CD8, and ED1 specific antibody staining. Perfusion with AAV2-PDGF-A or AAV2-PDGF-D significantly increased the number of graftinfiltrating CD4 ϩ (PϽ0.05 and PϽ0.05; Figure 5A ) and CD8 ϩ T cells (PϽ0.001 and PϽ0.01; Figure 5B ), and ED1 ϩ macrophages (PϽ0.05 and PϽ0.01; Figure 5C , respectively), when compared to the AAV2-EGFP-perfused allografts. For representative microphotographs please see supplemental Figure III .
AAV2-Mediated PDGF-A, PDGF-C, and PDGF-D Gene Transfer Increases Allograft TGF-␤1 mRNA Expression
As PDGF ligands may also have indirect effects on mesenchymal cells, we decided to investigate whether AAV-PDGF-A-D perfusion alters allograft expression of genes associated with cell survival, inflammation, endothelial-tomesenchymal transition, fibrosis, and arteriosclerosis. [27] [28] [29] RT-PCR analysis revealed that AAV2-mediated gene transfer of PDGF-A (PϽ0.05), PDGF-C (PϽ0.05), and PDGF-D (PϽ0.05), significantly increased profibrotic TGF-␤1 mRNA levels ( Figure 6A ). Smad2 phosphorylation was detected at the edge of fibrotic areas of cardiac allografts indicating activation of the TGF-␤1 pathway ( Figure 6B ). No significant changes were seen in bFGF, NF-B, VEGF, and antiapoptotic Bcl-2/Bax mRNA expression levels ( Figure 6C through  6F) . These results indicate that both direct effects on PDGFR ϩ fibroblasts and indirect effects through TGF-␤1 
Discussion
The PDGF family members provide important signals for mesenchymal cells during normal blood vessel development, and for example wound healing, but improper PDGF activa- tion is a driving force in many fibroproliferative diseases. 17, 18 Previous findings indicate that PDGF signaling regulates pathological SMC proliferation and arteriosclerosis in chronically-rejecting cardiac allografts, 24 but so far, the precise role of different PDGF members-especially the new ligands PDGF-C and -D-in transplanted hearts has remained unknown. Such knowledge could be used to develop therapeutic strategies that specifically target PDGF-mediated pathological effects while sparing possible PDGF-mediated physiological effects. Here, we found that the balance of PDGF ligands and receptors is changed in the proinflammatory heart transplant milieu in favor of increased PDGF-A/C/R-␣ activation. In addition, overexpression of PDGF-A, -C, and -D increased cardiac allograft arteriosclerosis and fibrosis while overexpression of PDGF-B did not mediate proarteriosclerotic or profibrotic effects. Immunologic and nonimmunological injury to the transplanted heart results in upregulation of several proinflammatory cytokines and growth factors 21, 23 that are involved in the development of chronic rejection. We show in this study that the expression pattern of the PDGF family members is changed in favor of increased PDGF-A/C/R-␣ activation in cardiac allografts challenged with severe acute rejection, or chronic rejection with ongoing inflammation, fibrosis, and arteriosclerosis. PDGFR-␣ expression was primarily increased in media and intima of arteries, and also in cardiomyocytes, and its ligands PDGF-A and -C were found in allograft-infiltrating inflammatory cells, cardiomyocytes, and intima of arteries. These findings suggest that in addition to PDGF-A, 25 also the new PDGF-family member PDGF-C may provide mitogenic signals for PDGFR-a ϩ mesenchymal cells in cardiac allografts. Similarly, PDGF-C is also induced in other situations with inflammation, injury, and fibrosis such as in coxsachievirus B3-induced myocarditis 30 and in kidney glomerular diseases. 31 Interestingly, both PDGF-A and -C are regulated by the early growth response gene-1 (EGR-1), 32,33 a transcription factor that is also involved in the development of chronic rejection. 34, 35 Increased EGF-1 activation could therefore form a common molecular basis for the upregulation of both PDGF-A and PDGF-C in cardiac allografts. In addition to PDGF-A and PDGF-C, also the expression of their receptor PDGFR-␣ was upregulated during cardiac allograft rejection. This is consistent with previous findings of ours and others that proinflammatory cytokines such as TNF-␣, 36 IL-1␤, 37 and TGF-␤ 38 induce PDGFR-␣ expression in VSMCs thereby rendering them responsive to PDGF-Amediated mitogenic signals. 24 As embryogenetic studies with knock-out mice show that PDGF-A and PDGF-C are mainly responsible for PDGFR-␣ signaling, 11 our results indicate an increased activation of PDGF-A/C/R-␣ pathway in transplanted hearts.
Although PDGF-B may bind to PDGFR-␣, the effects of both PDGF-B and -D are mainly mediated through PDGFR-␤. 13, 15, 16 We found that the mRNA levels of PDGFR-␤ and PDGF-B remained unchanged, and those of PDGF-D were decreased in acute and chronic cardiac allograft rejection. This could imply that in contrast to PDGF-A/C/R-␣ expression, PDGF-B/D/R-␤ signaling pathway is not activated in the proinflammatory cardiac allograft milieu. The decrease in PDGF-D mRNA levels in acute and chronic cardiac allograft rejection is surprising as PDGF-D mRNA is elevated in various kidney injury models. 39 However, paralleling our findings in the heart, bleomycin-induced lung injury increases the mRNA levels of PDGF-C and decreases those of PDGF-D. 40 Interestingly, despite the reduction of PDGF-D at the mRNA level, our results indicate a switch in PDGF-D protein production, as PDGF-D immunoreactivity was diminished in allograft endothelium but increased in allograft-infiltrating inflammatory cells.
To determine the pathological and physiological effects of different PDGF ligands in cardiac allografts, PDGF-A-D ligands were overexpressed in the transplanted hearts using AAV2-mediated gene transfer. Overexpression of PDGF-A, PDGF-C, and PDGF-D increased the development of chronic rejection, whereas PDGF-B did not have profibrotic or proarteriosclerotic effects. As our characterization studies revealed that endogenous PDGF-A/C/R-␣ expression was increased while the levels of PDGF-D were decreased in cardiac allografts, PDGF-A and PDGF-C may be the main fibroproliferative PDGF ligands in transplanted hearts. Interestingly, a previous experimental heart transplantation study showed that exogenous PDGF-A increased intimal hyperplasia whereas PDGFR-␣ inhibition attenuated the process. 25 Also, in the same study, PDGF-A inhibition with monoclonal antibodies failed to reduce intimal hyperplasia. 25 This apparent discrepancy could be explained by the presence of other PDGFR-␣ ligands than PDGF-A, and our present findings indicate that PDGF-C is sufficient to mediate pathological fibroproliferation in transplanted hearts. Thus, simultaneous targeting to both PDGF-A and PDGF-C, or inhibition of their common receptor PDGFR-␣, may be needed to prevent chronic rejection. The fibroproliferative role of PDGF-C in the heart is also supported by the finding that transgenic overexpression of PDGF-C in mouse hearts leads to cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. 5 Interestingly, overexpression of PDGFR-␤ ligands PDGF-B and PDGF-D yielded different results as PDGF-D increased allograft inflammation, fibrosis, and arteriosclerosis whereas PDGF-B lacked these pathological effects. This discrepancy may be explained by structural differences of the ligands-namely the presence of the ECM-binding retention motif in PDGF-B but not in PDGF-D. 12 This decreases the solubility of PDGF-B and may therefore affect its biological effects. As we found PDGFR-␤ expression in allograftinfiltrating inflammatory cells, it is possible that the soluble ligand PDGF-D promoted recruitment of these cells to the cardiac allograft. Similarly, overexpression of PDGF-D is more potent than that of PDGF-B in macrophage recruitment to the skin and skeletal muscle. 41 Previous studies also show that cardiac PDGF-D overexpression leads to myocardial fibrosis and VSMC proliferation 3, 6 paralleling the profibrotic effects of PDGF-D in the present study.
Although PDGF-ligands have direct effects on fibroblasts, 4 -6 we also investigated whether AAV2-PDGF perfusion altered other mediators of fibrosis and arteriosclerosis in cardiac allografts. Interestingly, the profibrotic effects of PDGF-A, PDGF-C, and PDGF-D overexpression were accompanied by a significant upregulation of allograft TGF-␤1 mRNA levels. In addition, we found phosphorylated Smad2 in the edge of fibrotic and healthy myocardium indicating activation of TGF-␤1 signaling in the perifibrotic areas. Our findings thus imply that in addition to the previously-reported direct fibrotic effects of PDGF-A, -C, and -D, 4 -6 these ligands also contributed to fibrosis through indirect TGF-␤1mediated effects, possibly also involving endothelial-tomesenchymal transition. 27 In conclusion, these results provide important insight in the divergent roles of different PDGF ligands and receptors in the proinflammatory heart allograft milieu. Our results show that primarily PDGF-A/C/R-␣ expression is induced in cardiac allografts, and that overexpression of PDGF-A, -C, and -D-but not of PDGF-B-increased cardiac allograft arteriosclerosis and fibrosis. These results could be used to develop therapeutic strategies against chronic rejection which specifically target PDGF-mediated pathological effects while sparing possible PDGF-mediated physiological effects.
